Back to top

cell-therapy: Archive

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNPositive Net Change BEAMPositive Net Change NTLAPositive Net Change